Evaxion A/S American Depositary Share (EVAX) — Analysis Summary
Evaxion A/S American Depositary Share (EVAX) has a market cap of $26.27M with year-over-year revenue growth of +125.1%. Net margin stands at -102.4%. The stock trades at a P/E ratio of -3.4.
Key Takeaways
- Revenue changed +125.1% year-over-year
- Net margin of -102.4%
- P/E ratio of -3.4
Compared with its sector, EVAX posted revenue growth of +125.1% and trades at a P/E of -3.4.
Evaxion A/S American Depositary Share (EVAX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -122.7% — severe operating losses
Net margin at -102.4% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Employees
46
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.